




Republic of the Philippines  
**PHILIPPINE HEALTH INSURANCE CORPORATION**

Citystate Centre, 709 Shaw Boulevard, Pasig City  
Healthline 637-9999 [www.philhealth.gov.ph](http://www.philhealth.gov.ph)

PhilHealth



Ka-Pamilya Mo!

15 November 2004

**PHILHEALTH CIRCULAR**

No. 26, s-2004

*WTO*

**TO :** ALL ACCREDITED HEALTH CARE PROVIDERS,  
CLAIMS PROCESSING DEPARTMENTS –  
NATIONAL CAPITAL REGION AND PHILHEALTH  
REGIONAL OFFICES (PROs), AND ALL OTHERS  
CONCERNED

**SUBJECT :** Reimbursement of claims for drugs listed in the PNDF  
Volume One, Sixth Edition- Sections 2, 7, 8, 13, 14, and 15

The National Formulary Committee of the Department of Health has released the official list of drugs under the following sections: 2.0 Drugs Affecting the Muskuloskeletal System and Joints, 7.0 Respiratory Drugs, 8.0 Anti- Allergics, 13.0 Gastrointestinal Drugs, 14.0 Hormones and Hormone Antagonists and 15.0 Drugs Acting on the Uterus of latest edition of the Philippine National Drug Formulary (PNDF) Volume One (1), Sixth (6<sup>th</sup>) edition, as approved by the Secretary of Health.


Pursuant to Section 37 of Republic Act 7875 and PhilHealth Board Resolution No. 265 s. 1999 which provides for the use of the latest edition of the PNDF for reimbursement, the said list of drugs shall be implemented as follows:

1. Newly listed drugs and drug preparations that are now included in Sections 2.0, 7.0, 8.0, 13.0, 14.0, and 15.0 of the PNDF, Volume 1, 6<sup>th</sup> edition (Annexes 1-6), **shall be compensable for claims with discharge dates starting December 1, 2004.**
2. Denial of PhilHealth coverage or reimbursement of delisted drugs and drug preparations for the above mentioned sections of the PNDF shall be held in abeyance pending the completion of the entire PNDF list and provision of reasons for the deletion of the same by the National Formulary Committee.
3. Clarification is also made here that **bupivacaine injection 0.5% 4 mL ampul with 8% dextrose (as hydrochloride)** which is included in the newly listed drug preparations as per PhilHealth Circular No. 03 s- 2004 Annex 1 (Section 1.0 Drugs Acting on the Nervous System) is the same as **bupivacaine injection 0.5% (heavy), 4 mL ampul (spinal) (as hydrochloride)**.

The latter **preparation** of bupivacaine which does not appear in the 6<sup>th</sup> edition of the PNDF is not a true delisting but rather a renaming whereby the NFC has removed the word "heavy" and instead added the words "with 8% dextrose".

In view of this, we are amending PhilHealth Circular No. 03 s- 2004 Annex 2 (Section 1.0 Drugs Acting on the Nervous System) where **bupivacaine injection 0.5% (heavy), 4 mL ampul (spinal) (as hydrochloride)** shall be erased from the list of the delisted preparations. Therefore, **bupivacaine injection 0.5% (heavy), 4 mL ampul (spinal) (as hydrochloride)** is compensable.

All other issuances inconsistent with this circular are hereby repealed and modified accordingly.

  
**DR. FRANCISCO T. DUQUE III**  
Secretary  
President and CEO

## ANNEX 1

### NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION Section 2.0 DRUGS AFFECTING THE MUSCULOSKELETAL SYSTEM AND JOINTS

#### A. NEWLY LISTED DRUGS (compensable by December 1, 2004)

GENERIC NAME	ROUTE	PREPARATION
Alendronate	Oral:	5 mg, 10 mg and 70 mg tablet (as sodium)
Alfacalcidol	Oral:	0.5 mcg, 0.25 mcg and 1 mcg tablet 0.25 mcg capsule
Calcitriol	Oral:	0.25 mcg and 0.5 mcg capsule
Calcium carbonate	Oral:	tablet/ chewable tablet, equivalent to 500 mg and 600 mg elemental calcium
Conjugated equine estrogen	Oral:	300 mcg, 625 mcg and 1.25 mg tablet
Conjugated equine estrogen + medroxy- progesterone acetate	Oral:	625 mcg + 2.5 mg tablet 625 mcg + 5 mg tablet
Raloxifene	Oral:	60 mg tablet (as hydrochloride)

-Nothing follows

#### B. NEWLY LISTED DRUG PREPARATIONS (compensable by December 1, 2004)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Diclofenac	Oral:	50 mg enteric coated tablet or delayed release tablet (as sodium salt) 75 mg SR tablet (as sodium or potassium salt)
	Inj.:	25 mg/mL, 3 mL ampul (as sodium) (IM, IV) 37.5 mg/mL, 2 mL ampul (as sodium) (IM, IV)
Ibuprofen	Oral:	600 mg tablet 800 mg SR tablet
Methotrexate (1)	Oral:	2.5 mg, 5 mg and 10 mg tablet (as base)
	Inj.:	5 mg/mL, 3 mL vial (IM, IV) (as sodium salt)
		2.5 mg/mL 2 mL ampul/vial (IM, IV, Intrathecal) (as base)
		25 mg/mL 2 mL ampul/ vial (IM, IV, Intrathecal) (as base)
		10 mg/mL, 1 mL and 5 mL vial ( as base) 50 mg/mL, 1 mL vial (as base) 100 mg/mL, 5 mL , 10 mL and 50 mL vial (as base)
Naproxen	Oral:	500 mg base (550 mg) tablet (as sodium salt)
▼ Rocuronium (1)	Inj.:	10 mg/mL, 5 mL vial (IV) (as bromide) 10 mg/mL, 2.5 mL vial (IV) (as bromide)

-Nothing follows

## ANNEX 2

### NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDP VOL. ONE (1) SIXTH (6TH) EDITION Section 7.0 RESPIRATORY DRUGS

#### A. NEWLY LISTED DRUGS (compensable by December 1, 2004)

GENERIC NAME	ROUTE	PREPARATION
<b>Budesonide + formoterol</b>	Inhalation:	Dry Powder Inhaler (DPI): 80 mcg budesonide + 4.5 mcg formoterol (as fumarate dihydrate) x 60 and 120 doses with appropriate accompanying dispenser 160 mcg budesonide + 4.5 mcg formoterol (as fumarate dihydrate) x 60 and 120 doses with appropriate accompanying dispenser
<b>Formoterol</b>	Oral: Inhalation:	40 mcg tablet (as fumarate) DPI: 12 mcg/dose (as fumarate) with appropriate accompanying dispenser 4.5 mcg/dose x 60 doses (as fumarate dihydrate) with appropriate accompanying dispenser 9.0 mcg/dose x 60 doses (as fumarate dihydrate) with appropriate accompanying dispenser
<b>Fluticasone</b>	Inhalation:	DPI: 50 mcg/dose (as propionate) with appropriate accompanying dispenser 250 mcg/dose (as propionate) with appropriate accompanying dispenser Metered Dose Inhaler (MDI): 50 mcg/dose x 60 doses and 120 doses (as propionate) 125 mcg/dose x 60 doses and 120 doses (as propionate) Resp. Soln.: (for nebulization) 250 mcg/mL, 2 mL (unit dose) (as propionate)
<b>Fluticasone + salmeterol</b>	Inhalation:	DPI: 100 mcg fluticasone (as propionate) + 50 mcg salmeterol (as xinafoate) x 28 and 60 doses with appropriate accompanying dispenser 250 mcg fluticasone (as propionate) + 50 mcg salmeterol (as xinafoate) x 28 and 60 doses with appropriate accompanying dispenser 500 mcg fluticasone (as propionate) + 50 mcg salmeterol (as xinafoate) x 28 and 60 doses with appropriate accompanying dispenser MDI: 50 mcg fluticasone (as propionate) + 25 mcg salmeterol (as xinafoate) x 120 doses 125 mcg fluticasone (as propionate) + 25 mcg salmeterol (as xinafoate) x 120 doses 250 mcg fluticasone (as propionate) + 25 mcg salmeterol (as xinafoate) x 120 doses
<b>Ipratropium + fenoterol</b>	Inhalation:	MDI: 20 mcg ipratropium (as bromide) + 50 mcg fenoterol (as hydrobromide) x 10 mL doses Resp. Soln.: (for nebulization) 250 mcg ipratropium (as bromide) + 500 mcg fenoterol (as hydrobromide) per ml, 20 mL (multidose) 500 mcg ipratropium (as bromide) + 1.25 mg fenoterol (as hydrobromide) per 4 ml, (unit dose)

**A. NEWLY LISTED DRUGS (compensable by December 1, 2004)**

GENERIC NAME	ROUTE	PREPARATION
Ipratropium + salbutamol	Inhalation:	MDI: 21 mcg ipratropium (as bromide) + 120 mcg salbutamol x 200 doses x 10 mL Resp. Soln.: (for nebulization) 500 mcg ipratropium (as bromide anhydrous) + 2.5 mg salbutamol (as base) x 2.5 mL (unit dose)
Montelukast (1)	Oral:	4 mg and 5 mg chewable tablet (as sodium) 10 mg tablet (as sodium)
Tiotropium	Inhalation:	DPI: 18 mcg/dose (as bromide) with appropriate accompanying dispenser

-Nothing follows-

**B. NEWLY LISTED DRUG PREPARATIONS (compensable by December 1, 2004)**

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PPDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PPDF.

GENERIC NAME	ROUTE	PREPARATION
Beclometasone	Inhalation:	DPI: 200 mcg/dose (as dipropionate) with appropriate accompanying dispenser 400 mcg/dose (as dipropionate) with appropriate accompanying dispenser MDI: 50 mcg/dose x 100 doses (as dipropionate)
Butamirate	Oral:	50 mg SR tablet (as citrate)
Cromolyn sodium (sodium cromoglicate)	Inhalation:	DPI: 20 mg/dose with appropriate accompanying dispenser
Dextromethorphan (2)	Oral:	5 mg/mL syrup, 120 mL (alcohol- free) (as hydrobromide) 10 mg/5 mL syrup, 60 mL (alcohol- free) (as hydrobromide) 15 mg/5 mL syrup, 30 mL, 60 mL and 120 mL (alcohol- free) (as hydrobromide)
Hydrocortisone	Inj.:	powder, 100 mg, 250 mg and 500 mg vial (IV) (as sodium succinate)
Ipratropium	Inhalation:	Resp. Soln.: (for nebulization) 250 mcg/mL, 1 mL (unit dose) (as bromide)
Lagundi	Oral:	300 mg/5 mL syrup, 60 mL and 120 mL bottle
Methylprednisolone	Inj.:	powder 125 mg/mL, 2 mL vial + diluent vial (IM, IV, IV infusion) (as sodium succinate)
Prednisolone	Oral:	20 mg tablet 15 mg/5 mL syrup 20 mL and 30 mL (as sodium phosphate) 20 mg/5 mL syrup 30 mL and 60 mL (as sodium phosphate)
Prednisone	Oral:	10 mg and 20 mg tablet 30 mg film coated tablet 10mg/5 mL suspension, 30 and 60 mL
Procaterol	Inhalation:	MDI: 5 mcg/dose x 100 doses (as hydrochloride hemihydrate)
Salbutamol	Inhalation:	MDI: 100 mcg/dose x 300 doses (as sulfate)
Terbutaline	Oral:	2 mg tablet (as sulfate)
Theophylline (anhydrous) (B)	Oral:	200 mg and 300 mg SR tablet 400 mg SR capsule

-Nothing follows-

## ANNEX 3

### NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION Section 8.0 ANTI - ALLERGICS

#### NEWLY LISTED DRUG PREPARATIONS ( compensable by December 1, 2004)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Cetirizine	Oral:	1 mg/mL solution, 60 mL (as dihydrochloride) 5mg/5 mL syrup, 30 mL (as dihydrochloride)
Chlorphenamine (chlorpheniramine)	Oral: Inj.:	2.5 mg/5 mL syrup 60 mL (as maleate) 10mg/mL, 10 mL vial (IM, IV) (as maleate)
Diphenhydramine	Oral:	12.5 mg/5 mL syrup, 30 mL (alcohol- free) (as hydrochloride)
Famotidine	Oral:	10 mg tablet 20 mg film coated tablet 20 mg/5 mL powder for suspension, 60 mL
Hydroxyzine	Oral: Inj.:	2 mg/mL syrup 60 mL ( as hydrochloride or dihydrochloride ) 50 mg/mL, 1 mL vial (IM, IV)
Loratadine	Oral:	10 mg film coated tablet
Methylprednisolone	Inj.:	powder 125 mg/mL, 2 mL vial + diluent vial (IM, IV, IV Infusion) (as sodium succinate)
Prednisolone	Oral:	20 mg tablet 15 mg/5 mL syrup 20 mL and 30 mL (as sodium phosphate) 20 mg/5 mL syrup, 30 and 60 mL (as sodium phosphate)
Prednisone	Oral:	10 mg and 20 mg tablet 30 mg film coated tablet 10mg/5 mL suspension, 30 and 60 mL
Ranitidine	Inj.:	25mg/mL, 2 mL vial (IM, IV, IV Infusion) (as hydrochloride)

-Nothing follows

## ANNEX 4

### NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION Section 13.0 GASTROINTESTINAL DRUGS

#### NEWLY LISTED DRUG PREPARATIONS (compensable by December 1, 2004)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Aluminum hydroxide	Oral:	600 mg/5mL gel, 240 mL (for use of not more than 15 days)
Atropine	Oral:	600 mcg (equiv to 500 mcg atropine) tablet (as sulfate)
	Inj.:	600 mcg/mL, 1 mL ampul (IM, IV, SC) (as sulfate)
Bisacodyl	Oral:	5 mg delayed release tablet
Cimetidine	Oral:	100 mg/5 mL liquid, 30 mL, 60 mL, 120 mL
Dicycloverine (dicyclomine)	Oral:	10 mg/5 mL syrup 120 mL (as hydrochloride)
		5 mg/mL drops, 15 mL (as hydrochloride)
Domperidone	Oral:	1 mg/mL suspension, 30 mL
Famotidine	Oral:	10 mg tablet
		20mg/5mL powder for suspension, 60 mL
Glycerol (glycerin)	Rectal:	2.5 g suppository
Hyoscine	Inj.:	500 mcg/mL, 1 mL ampul (IM,IV) (as hydrobromide)
		200 mcg/mL, 1 mL ampul (IM,IV) (as hydrobromide)
Lactulose (for hepatic encephalopathy)	Oral:	3.3 g/5 mL (66 %) syrup, 200 mL
Mesalazine (1)	Oral:	250 mg and 500 mg enteric coated tablet 500 mg enteric slow release tablet
	Rectal:	1 g suppository
Metoclopramide	Inj.:	5mg/mL, 3 mL ampul (IM, IV) (as base and as hydrochloride)
		5mg/5 mL syrup, 60 mL (as base)
Omeprazole	Oral:	40 mg capsule
Ranitidine	Oral:	150 mg and 300 mg effervescent tablet (as hydrochloride)
		150 mg and 300 mg tablet (as base)
		75 mg tablet (as base and as hydrochloride)
Standard senna concentrate	Oral:	374 mg tablet
		337 mcg/ 3 g granules, 30 g bottle
Sucralfate	Oral:	1 g/5 mL gel sachet
Ursodeoxycholic acid	Oral:	100 mg and 200 mg tablet (N.B. for primary biliary cirrhosis)

-Nothing follows

## ANNEX 5

### NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION Section 14.0 HORMONES AND HORMONE ANTAGONISTS

#### A. NEWLY LISTED DRUGS (compensable by December 1, 2004)

GENERIC NAME	ROUTE	PREPARATION
Acarbose	Oral:	50 mg and 100 mg tablet
Alfuzosin	Oral:	2.5 mg film- coated tablet (as hydrochloride) 5 mg film- coated tablet (SR)(as hydrochloride) 10 mg tablet (once a day) (as hydrochloride)
Conjugated equine estrogen + medroxy progesterone acetate	Oral:	625 mcg + 2.5 mg tablet 625 mcg + 5 mg tablet
Finasteride	Oral:	5 mg tablet
▼Goserelin	Inj.:	3.6 mg depot solution, pre- filled syringe (SC) (as acetate) 10.8 mg depot solution, pre- filled syringe (SC) (as acetate)
Leuprorelin	Inj.:	powder, 1.88 mg single dose with syringe (IM,SC) (as acetate) powder, 3.75 mg single dose with syringe (IM,SC) (as acetate) powder, 11.25 mg depot solution, vial + syringe (IM,SC) (as acetate)
Lynestrenol	Oral:	500 mcg tablet
Rosiglitazone	Oral:	4 mg and 8 mg tablet (as maleate)
Tamsulosin	Oral:	200 mcg capsule (as hydrochloride)

-Nothing follows-

#### B. NEWLY LISTED DRUG PREPARATIONS ( compensable by December 1, 2004)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Bethamethasone	Oral: Inj.:	<b>500 mcg tablet (as base)</b> <b>5 mg (as dipropionate) + 2 mg</b> <b>(as sodium phosphate)</b> <b>per mL, 1 mL ampul</b> <b>(IM, ID, Intraarticular, Intralesional)</b> <b>(not for IV or SC use)</b>
▼Desmopressin	Oral:	<b>200 mcg tablet (as acetate)</b>
Dexamethasone	Inj.:	<b>4mg/mL, 2 mL ampul (IM,IV)</b> <b>(as sodium phosphate)</b>
Ethinylestradiol + levonorgestrel (triphasic)	Oral:	<b>30 mcg ethinylestradiol+ 50 mcg</b> <b>levonorgestrel per tablet</b> <b>30 mcg ethinylestradiol+ 125 mcg</b> <b>levonorgestrel per tablet</b> <b>40 mcg ethinylestradiol+ 75 mcg</b> <b>levonorgestrel per tablet</b>
Ethinylestradiol + norethisterone	Oral:	<b>35 mcg ethinylestradiol+ 400 mcg</b> <b>norethisterone acetate per tablet</b>
Glicazide (B)	Oral:	<b>30 mg MR tablet</b>
Human chorionic gonadotrophin (HCG) (1, 2)	Inj.:	<b>lyophilized powder, 1,000 IU vial +</b> <b>1 mL solvent (IM)</b> <b>lyophilized powder, 1,500 IU ampul +</b> <b>1 mL solvent (IM)</b> <b>lyophilized powder, 5,000 IU vial +</b> <b>1 mL solvent (IM)</b>

**B. NEWLY LISTED DRUG PREPARATIONS (compensable by December 1, 2004)**

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PPDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PPDF.

GENERIC NAME	ROUTE	PREPARATION
Human growth hormone (biosynthetic) (1, 2)	Inj.:	lyophilized powder, 4 mg vial + 2 mL diluent (SC)
Hydrocortisone	Inj.:	powder, 100 mg, 250 mg and 500 mg vial (IV) (as sodium succinate)
Medroxyprogesterone (2)	Inj.:	50 mg/mL, 3 mL vial + syringe (IM) (as acetate) ( N.B. Use one (1) inch long needle)
Metformin (B)	Oral:	500 mg film coated tablet (as hydrochloride) 1 g tablet (as hydrochloride)
Methylprednisolone	Inj.:	40 mg/mL, 1 mL suspension vial (IM, Intralesional) (as sodium acetate) lyophilized powder, 125 mg vial (IM,IV) (as sodium succinate) lyophilized powder, 500 mg vial (IM,IV) (as sodium succinate) lyophilized powder, 1g vial (IM,IV) (as sodium succinate) powder 62.5 mg/mL , 4 mL vial (as sodium succinate) powder 500 mg/8.0 mL vial + diluent vial (IM, IV, IV infusion) (as sodium succinate)
Norethisterone (2)	Inj.:	200 mg/mL, 1 mL ampul, (IM) (as enanthate)
Prednisolone	Oral:	20 mg tablet 15 mg/5 mL syrup, 30 mL (as sodium phosphate) 20 mg/5 mL syrup, 30 mL and 60 mL (as sodium phosphate)
Prednisone	Oral:	10 mg and 20 mg tablet 30 mg film coated tablet 10 mg/5 mL suspension, 30 mL and 60 mL
Thiamazole (methimazole)	Oral:	10 mg tablet
Triamcinolone	Inj.:	10 mg/mL, 1 mL vial (as acetonide) (Intraarticular, Intradermal) 40 mg/mL, 1 mL ampul (as acetonide) (Intraarticular, Intralesional, Intradermal)

-Nothing follows-

## ANNEX 6

### NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION Section 15.0 DRUGS ACTING ON THE UTERUS

#### A. NEWLY LISTED DRUGS (compensable by December 1, 2004)

GENERIC NAME	ROUTE	PREPARATION
Magnesium sulfate (1)	Inj.:	250 mg/mL, 2 mL and 10 mL ampul, and 10 mL and 20 mL vial (IM, IV) (as heptahydrate); 500 mg/mL, 2 mL and 10 mL ampul (IM, IV) (as heptahydrate)
	-Nothing follows-	

#### B. NEWLY LISTED DRUG PREPARATIONS (compensable by December 1, 2004)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Isoxsuprine	Oral:	40 mg retard capsule (as hydrochloride)
	-Nothing follows-	